Proteome Sciences PLC AGM Statement and Result of AGM (2782D)
25 April 2017 - 10:34PM
UK Regulatory
TIDMPRM
RNS Number : 2782D
Proteome Sciences PLC
25 April 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
AGM Statement and Result of AGM
At the Company's AGM held today the Chairman, Christopher
Pearce, made the following statement:
"As stated in our recent results, we expect 2017 to be a
transformational year for Proteome Sciences. The combination of
strong revenue growth during 2016 and operational initiatives to
simplify our strategy, consolidate our resources and broaden our
commercial capability, have put the Company in a good position to
take advantage of the increasing opportunities afforded by
quantitative proteomics. Trading remains in line with management
expectations."
All resolutions at the AGM were duly passed.
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer Tel:
+44 (0)1932 865065
Dr Ian Pike, Chief Scientific
Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated
Adviser/Broker) Tel: +44 (0)20 7220
Geoff Nash/James Thompson 0500
Tony Quirke (broking)
IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Tel: +44 (0)20 3053
Herring/Miles Nolan 8671
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) )
and for the discovery, validation and assay development of protein
biomarkers. The company has its headquarters in Cobham, UK, with
laboratory facilities in Frankfurt, Germany from where the PS
Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein
biomarkers for diagnostic and treatment applications in important
areas of human therapeutics such as cancer, stroke and Alzheimer's
disease, and these are available for license.
This announcement contains inside information for the purpose of
Article 7 of EU Regulation 596/2014.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMPGUGWCUPMGPA
(END) Dow Jones Newswires
April 25, 2017 08:34 ET (12:34 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024